



ABSTRACT 2016

<p>The health burden of Primary Biliary Cholangitis in Switzerland SwissPBC, SASL 36. [Annual meeting of the Swiss Society of Gastroenterology (SGG), Interlaken, 2016 September 22-23] Terziroli Beretta-Piccoli B • Cerny A • Carbone M • Giostra E • Semela D • Mertens J • Hessler R • Helbling B • Stickel F • Khalid-de Bakker C • Bihl F • Stirnimann G • Invernizzi P.</p>
<p>Real life experience with direct antiviral agent (DAA) treatment of chronic HCV infection in three Swiss centers. [Annual meeting of the Swiss Society of Gastroenterology (SGG), Interlaken, 2016 September 22-23] Bachofner JA • Valli PV • Kroeger A • Bergamin I • Kuenzler P • Baserga A • Braun D • Seifert B • Moncsek A • Fehr J • Semela D • Magenta L • Müllhaupt B • Terziroli Beretta-Piccoli B • Mertens J.</p>
<p>DAA treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers FIB-4 and APRI. [Annual meeting of the Swiss Society of Gastroenterology (SGG), Interlaken, 2016 September 22-23] Bachofner JA • Valli PV • Kroeger A • Bergamin I • Kuenzler P • Baserga A • Braun D • Seifert B • Moncsek A • Fehr J • Semela D • Magenta L • Müllhaupt B • Terziroli Beretta-Piccoli B • Mertens J.</p>
<p>Hepatitis E as a cause of acute Hepatitis acquired in Switzerland. [poster presentation at Annual meeting of the Swiss Society of Gastroenterology (SGG), Interlaken, 2016 September 22-23] Fraga M, Doerig C • Moulin H • Bihl F • Brunner F • Muellhaupt B • Semela D • Stickel F • Terziroli B • Aubert V • Telenti A • Greub G • Sahli R • Moradpour D.</p>
<p>Hepatitis C treatment on PWUD in the DAA's era: high rate of virological response in the real life. [5 th International Symposium on Hepatitis Care in Substance Users (INHSU), Oslo, 2016 September 7-9] Moriggia A • Balmelli M • Baserga A • Gurtner V • Hagara D • Magenta L • Robatto A • Terziroli Beretta-Piccoli B • Cerny A et al.</p>
<p>High prevalence of liver fibrosis among people attending addiction clinics and rehabilitation facilities in southern Switzerland: results of two different screening programs for liver disease. [5th International Symposium on Hepatitis Care in Substance Users (INHSU), Oslo, 2016 September 7-9] Moriggia A • Magenta L • Terziroli Beretta-Piccoli B • Gurtner V • Fossati E • Weimann M • Cerny A.</p>
<p>Prospective data on People who use drugs in Switzerland: the SAMMSU cohort. [Poster presentation at 6° Giornata della Ricerca Clinica della Svizzera Italiana, Lugano, 2016 Marzo 18] Moriggia A • Cerny A • Bregenzer A • Bruggmann P • Castro E • Rothen E • Rougemont M • Staehelin C • Thurnheer C • Vernazza P • Scheidegger C.</p>
<p>Use of direct anticoagulants (DOACs) in patients with splanchnic vein thrombosis and/or cirrhosis. [Poster presentation at 6° Giornata della Ricerca Clinica della Svizzera Italiana, Lugano, 2016 Marzo 18] De Gottardi A • Trebicka J • Klinger CH • Plessier A • Seijo S • Terziroli Beretta-Piccoli B • Magenta L • Semela D • Buscarini E • Langlet PH • Görtzen J • Puente A • Müllhaupt B • Navascuès C • Nery F • Deltenre P • Turon F • Engelmann C • Arya R • Caca K • Peck-Radosavljevic M • Valla D • Garcia-Pagan JC on behalf of the VALDIG Investigators.</p>
<p>The health burden of Primary Biliary Cholangitis in Switzerland – SwissPBC SASL 36. [Poster presentation at 6° Giornata della Ricerca Clinica della Svizzera Italiana, Lugano, 2016 Marzo 18] Terziroli Beretta-Piccoli B • Cerny A • Carbone M • Giostra E • Semela D • Mertens J • Hessler R • Helbling B • Stickel F • Khalid-de Bakker C • Bihl F • Stirnimann G • Invernizzi P.</p>